Life Sciences Treasury: A Capital Allocation Balancing Act
# AI
# Capital Allocation
J&J treasurer Fran Dougherty discusses the mission of life sciences treasury: capital allocation, growth and value creation.
Life sciences treasurers have to balance various—sometimes competing—priorities, including helping their companies deploy capital and generate returns while running faster and more efficiently. In a sector where growth depends heavily on R&D, business development and M&A, capital allocation decisions give treasury a direct role in funding innovation, shaping growth and creating shareholder value.
That was one of the key takeaways from the H1 meeting of NeuGroup for Life Sciences Treasurers. In a new NeuGroup Insights video you can watch by clicking the play button below, Fran Dougherty, treasurer at Johnson & Johnson, discusses how treasury leaders at life sciences companies balance those priorities in practice, including the impact of AI.
“When you look at life sciences, the treasurer always plays such an important role on so many fronts,” he says. “The role that we play, really being financial stewards to cash and capital allocation, that won’t change. How we do that, I think that will clearly change.”
What brings treasurers together. Mr. Dougherty said the meeting underscored how much life sciences treasurers have in common, even across companies with different business models, balance sheets and growth priorities.
He says that peer forums like NeuGroup meetings give professionals a way to compare approaches and discuss shared challenges about how to support the business, manage risk and collaboratively make the function more efficient in a noncompetitive setting. “We’re all facing very similar opportunities and challenges,” he says in the video. “And I think it’s a really great opportunity for us to do this on a regular basis.”
